title: Pharmacovigilance in practice: erythropoiesis-stimulating agents.
abstract: Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other problems related to medical products after they have been licensed for marketing. The purpose of PV is to advance the safe use of marketed medical products. Regulatory agencies and license holders collaborate to collect data reported by health care providers, patients, and the public as well as data from systematic reviews, meta-analyses, and individual clinical and nonclinical studies. They validate and analyze the data to determine whether safety signals exist, and if warranted, develop an action plan to mitigate the identified risk. Erythropoiesis-stimulating agents (ESAs) provide an example of how PV is applied in reality. Among other approved indications, ESAs may be used to treat anemia in patients with chemotherapy-induced anemia. ESAs increase hemoglobin levels and reduce the need for transfusions; they are also associated with a known increased risk of thromboembolic events. Starting in 2003, emerging data suggested that ESAs might reduce survival. As a result of PV activities by regulatory agencies and license holders, labeling for ESAs addresses these risks. Meta-analyses and individual clinical studies have confirmed that ESAs increase the risk of thromboembolic events, but when used as indicated, ESAs have not been shown to have a significant effect on survival or disease progression. Ongoing safety studies will provide additional data in the coming years to further clarify the risks and benefits of ESAs.
authors.affiliation: Sundsvall Hospital, Sundsvall, Sweden.
authors.forename: Michael
authors.initials: M
authors.lastname: Hedenus
authors.forename: Heinz
authors.initials: H
authors.lastname: Ludwig
authors.forename: David H
authors.initials: DH
authors.lastname: Henry
authors.forename: Eduard
authors.initials: E
authors.lastname: Gasal
mesh_terms: D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D059451:Biosimilar Pharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use; D006397:Hematinics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D060735:Pharmacovigilance; D017410:Practice Guidelines as Topic
chemical_list: D000970:Antineoplastic Agents; D059451:Biosimilar Pharmaceuticals; D006397:Hematinics
keywords: Adverse event; chemotherapy induced anemia; erythropoiesis-stimulating agent; pharmacovigilance; safety signal